EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Peptide Mimics of the Human Acetylcholine Receptor Main Immunogenic Region for Treating Myasthenia Gravis

Vu B Trinh iD, Robert H Fairclough

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms26010229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Vu B Trinh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Davis School of Medicine, University of California, 1515 Newton Court, Davis, CA 95618, USA. Hauptthemen laut MEDLINE: Receptors, Cholinergic, Peptides, Myasthenia Gravis. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: New York MG Alliance, UC Davis Health Ventures, Myasthenia Gravis Foundation of California.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have designed and produced 39 amino acid peptide mimics of the Torpedo and human acetylcholine receptors’ (AChRs) main immunogenic regions (MIRs). These conformationally sensitive regions consist of three non-contiguous segments of the AChR α-subunits and are the target of 50–70% of the anti-AChR autoantibodies (Abs) in human myasthenic serum and in the serum of rats with a model of that disease, experimental autoimmune myasthenia gravis (EAMG), induced by immunizing the rats with the Torpedo electric organ AChR. These MIR segments covalently joined together bind a significant fraction of the monoclonal antibodies (mAbs) raised in rats against electric organ AChR. Many of these mAbs cross react with the rat neuromuscular AChR MIR and induce myasthenic symptoms when injected into naïve rats. The human MIR mimic peptide (H39MIR) is evolutionarily related to that of the Torpedo electric organ MIR mimic peptide (T39MIR) with eight amino acid differences between the two MIR mimics. The mAbs raised to the electric organ AChR MIR cross react with the human and scores of other species’ neuromuscular AChRs. However, the mAbs do not cross react with the H39MIR mimic attached to the N-terminus of an intein–chitin-binding domain (H39MIR-IChBD) even though they do bind to the T39MIR-IChBD construct. To account for this difference in binding anti-MIR mAbs, each of the eight human amino acids was substituted individually into the T39MIR-IChBD, and four of them were found to weaken mAb recognition. Substituting the corresponding four Torpedo amino acids individually and in combination into the homologous positions in H39MIR-IChBD makes chimeric human MIR mimic peptides (T/H39MIR), some of which bind anti-MIR mAbs and anti-MIR Abs from rat EAMG and human MG sera. The best mAb binding chimeric peptide constructs may potentially serve as the basis of a diagnostic anti-MIR Ab titer assay that is both prognostic and predictive of disease severity. Furthermore, the best peptides may also serve as the targeting element of a non-steroidal antigen-specific treatment of MG to remove anti-AChR MIR Abs, either as fused to the N-terminals of the human immunoglobin Fc fragment or as the targeting component of a T cell chimeric autoantibody receptor (CAAR) directed to anti-MIR memory B cells for elimination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CholinergicPeptidesMyasthenia GravisHumansAnimalsRatsAntibodies, MonoclonalAutoantibodiesAmino Acid SequenceMyasthenia Gravis, Autoimmune, ExperimentalTorpedo

Stichwörter der Autor:innen

human acetylcholine receptorimmunotherapymain immunogenic regionmyasthenia gravis

Substanzen

Receptors, CholinergicPeptidesAntibodies, MonoclonalAutoantibodies

Autor:innen und Institutionen

  • Department of Neurology, Davis School of Medicine, University of California, 1515 Newton Court, Davis, CA 95618, USA.
  • Biochemistry, Molecular, Cellular, and Developmental Biology Graduate Group, University of California, Davis, CA 95618, USA.
  • Biophysics Graduate Group, University of California, Davis, CA 95618, USA.

ORCID-Profile: Vu B Trinh

Förderung

  • New York MG Alliance
  • UC Davis Health Ventures
  • Myasthenia Gravis Foundation of California

Zitieren

APA

Trinh, V. B., & Fairclough, R. H. (2024). Development of Peptide Mimics of the Human Acetylcholine Receptor Main Immunogenic Region for Treating Myasthenia Gravis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26010229

Vancouver

Trinh VB, Fairclough RH. Development of Peptide Mimics of the Human Acetylcholine Receptor Main Immunogenic Region for Treating Myasthenia Gravis. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms26010229

BibTeX
@article{Trinh2024,
  author = {Trinh, Vu B and Fairclough, Robert H},
  title = {Development of Peptide Mimics of the Human Acetylcholine Receptor Main Immunogenic Region for Treating Myasthenia Gravis},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms26010229}
}
Kostenlos starten →